Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

This study evaluated the effects of exenatide, a novel incretin mimetic, in hyperglycemic patients with type 2 diabetes unable to achieve glycemic control with metformin-sulfonylurea combination therapy.

Who Took Part

The abstract describes 733 subjects taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the subjects and researchers unaware of who received Exenatide.

Some subjects received a placebo instead of Exenatide, giving a reference point.

A time span of 4 weeks appears in the methods.

(arms A and B) or placebo for 4 weeks.

Thereafter, arm A remained at 5 microg b.i.d. and arm B escalated to 10 microg b.i.d.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin, Hyperglycemia, Hypoglycemic Agents and Metformin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 733 subjects over 4 weeks.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (Diabetes care), a journal based in United States.

More context: the Exenatide compound page.